ANIMALS WITH TARGETED GENE DISRUPTION

Abstract: The invention provides transgenic non-human animals in which genes encoding colony-stimulating factors have been specifically disrupted, so that the animals do not express the respective factors. In specific embodiments the invention provides mice in which expression of GM-CSF, G-CSF and/or CSF-1 is disrupted. These animals do not produce any bioactive CSF of the respective type. They are useful as models for a variety of conditions, and particularly for testing of therapeutic methods.

Description: ANIMALS WITH TARGETED GENE DISRUPTION This invention relates to animals having specifically designed alterations in pre-existing endogenous genetic loci, eg. animals having targeted disruptions of specific genes. In particular, the invention relates to animals in which the gene for a colony-stimulating factor is disrupted so as to create a null allele, whereby the animal does not express any detectable colony-stimulating factor. The colony- stimulating factor is granulocyte-macrophage colony- stimulating factor or granulocyte colony-stimulating factor. In a preferred embodiment of the invention, the animal is a rodent such as a mouse. BACKGROUND OF THE INVENTION Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a haematopoietic growth factor which in vitro stimulates the survival, proliferation, differentiation and function of myeloid cells and their precursors, particularly neutrophil and eosinophil granulocytes and monocyte/macrophages (for review, see 1). The in vivo effects of GM-CSF have been studied in murine models by injecting pharmacological doses of GM-CSF (2), by generating GM-CSF transgenic mice (3), and by reconstituting lethally irradiated mice with bone marrow cells overproducing GM-CSF (4). These studies confirm the haematopoietic activity of GM-CSF in vivo, and suggest that excess levels of GM-CSF may be implicated in some disease processes. However, the usual physiological role of GM-CSF is not well defined (5). Endogenously-produced GM-CSF is not usually detectable in serum (6), and in humans altered serum levels have not correlated clearly with haematological or disease processes (1,6). It has been suggested that GM-CSF may be produced and act locally (1), but the cells producing GM-CSF in vivo have yet to be identified. Moreover, it is not clear whether GM-CSF is an essential regulator for steady-state production of granuloσytes and macrophages, or whether it is required as a regulator for emergenσy haematopoiesis in response to σhallenges such as bacterial infection. It is also not known whether GM-CSF is involved in the normal development of non-haematopoietic tissues. Granuloσyte σolony-stimulating faσtor (G-CSF) is a haematopoietic growth factor which in vitro controls granulopoiesis. It stimulates the survival, proliferation, differentiation and function primarily of neutrophil granuloσytes. As in the case of GM-CSF, the in vivo effects of G-CSF have been studied in murine models by injection of pharmacologiσal doses of G-CSF, and by reconstitution of lethally irradiated mice with bone marrow cells transformed with a retroviral vector carrying cDNA encoding G-CSF (reviewed in Reference 7). However, as with GM-CSF, the usual physiological role in vivo of G-CSF is unclear. It may act as a regulator in steady-state granulopoiesis, or may function as a regulator for emergency granulopoiesis in response to specific challenges requiring increased neutrophil production, such as infection (7) . G-CSF and its isolation, characterisation, and recombinant production have been extensively reviewed, for example papers cited in Referenσes 5 and 7. Until reσently, genetiσ studies depended upon the discovery of random mutations (either spontaneous or induced) or of pre-existing genetic polymorphisms. However, following the rapid development of recombinant DNA technology and of identification of specific genes, particularly in mice, by analogy to genes from other species or from the biochemistry of the protein products which they encode, methods for specifically-targeted deletion or modification of genes have been developed. Provided that a cloned, genomic fragment of the chosen genetic locus is available, it is possible to generate null alleles by disruption of the gene, to modify functional properties of the gene such as transcriptional pattern, mRNA or protein maturation pattern, or to modify the ability of the protein to interact with other gene products. This is achieved by using conventional recombinant DNA methods to introduce the desired mutation into a cloned DNA sequence of the chosen gene; the mutation is then transferred by means of homologous recombination into the genome of a pluripotent embryonic stem cell (ES cell) . The ES cells thus produced are transferred by microinjection into mouse blastocysts in order to generate germ-line chimeras. Animals homozygous for the desired mutation are then generated by interbreeding of heterozygous siblings. These techniques are now widely used, and have been employed to generate lineages of mice in which a variety of genes are disrupted; these mice are often referred to as "knock-out" miσe. Many of these mutations are lethal, causing death early in embryonic life or in the perinatal period. The teσhnique has been particularly successful in producing "knock-out" mice in which genes for molecules of immunological importance or for growth factors are deleted. The techniques are well established, and a variety of marker genes and genes employed to assist in selection of cells which have undergone homologous recombination rather than random integration of DNA are available. A number of reviews have been published [7 to 11] , and techniques for generation of transgenic mice in general are reviewed in International Patent Application No. WO 91/13150 by Ludwig Institute for Cancer Research. While such gene targeting is useful in the production of mouse models for genetically-determined human diseases, which models can be used for testing potential therapies, and while the techniques are well established in principle, it is not possible to predict in advance whether an animal line bearing a given targeted gene disruption can be generated, or if so how readily practicable generation of such a model will be and the best experimental approach to utilise. In particular, the frequency of transformation of the ES cells varies widely, from as little as 1 in 40,000 to as much as 1 in 150. While some of the factors involved in optimisation of transformation frequency are known, suσσess is not easy to prediσt. We have generated GM-CSF defiσient and G-CSF defiσient miσe through targeted disruption of the GM-CSF and G-CSF genes respeσtively in embryonic stem cells. We have surprisingly found that while GM-CSF deficient mice have no major perturbation of haematopoiesis, they all have abnormal lungs and are prone to lung infeσtions , impliσating GM-CSF as being essential for normal pulmonary physiology and resistance to local infection. GM-CSF deficient miσe are useful as a model system for the syndrome of alveolar proteinosis, and are partiσularly useful as a model system for the study of opportunistic infeσtions and infeσtions which are intractable to currently available therapies. G-CSF deficient mice are neutropaenic, but have normal levels of monocytes in the periphery. They are prone to sub-clinical infections, and will be useful in testing the efficaσy of anti-miσrobial agents, espeσially in settings of inσreased vulnerability. They will also be useful in assessing the virulence of microorganisms. SUMMARY OF THE INVENTION Acσording to one aspeσt of the invention, there is provided a non-human animal σarrying a disruption of a gene enσoding a colony stimulating factor. Preferably the animal is a rodent, for example a mouse, rat, rabbit or hamster, and more preferably is a mouse. In one preferred embodiment, this aspect of the invention provides a non-human animal carrying a disruption of the gene enσoding granuloσyte-maσrophage σolony- stimulating-faσtor (GM-CSF) , suσh that expression of GM-CSF is disrupted. Preferably the spleen cells from the animal are incapable of producing detectable levels of bioactive GM-CSF. Also preferably the gene encoding GM-CSF is completely inactivated. Most preferably the animal carries a mutation σomprising deletion of exons 1 and 2 and intron 1 between Seal and Smal restriσtion sites of the gene enσoding GM-CSF. In an alternative embodiment, this aspeσt of the invention provides a non-human animal carrying a disruption of the gene encoding granulocyte σolony-stimulating faσtor (G-CSF), such that expression of the colony-stimulating faσtor is disrupted. Preferably the lung σells from the animal are inσapable of produσing deteσtable levels of bioaσtive G-CSF. Also preferably the gene enσoding G-CSF is σompletely inaσtivated. Most preferably the animal σarries a mutation σomprising a deletion from the Nσol restriσtion site in exon 1 to the -BamHI restriσtion site in exon 3 of the gene enσoding G-CSF. Optionally the animals may also σarry one or more additional mutations whiσh result in disruption of a speσifiσ gene. For example, a GM-CSF defiσient animal -may also σarry a mutation resulting in disruption of the gene for G-CSF, or viσe versa. Again the animal is preferably a mouse, and the additional gene disruption may alternatively be targeted to a gene encoding a growth factor selected from the group consisting of colony-stimulating-faσtor-1 (CSF-1); leukaemia inhibitory factor (LIF) , and transforming growth factor-βl (TGF-βl), or a σytokine, preferably an interleukin, inσluding, but not limited to, an interleukin seleσted from the group consisting of interleukin-2, interleukin-3 and interleukin-6. Such double or multiple knock-out animals σan be generated by σrossing of animals in whiσh the gene enσoding GM-CSF or G- CSF is disrupted with animals in whiσh the other desired gene(s) is disrupted. For example, the osteopetrotiσ mouse, a line which originated by spontaneous mutation, is known to be deficient in CSF-1, and has decreased levels of monocytes/maσrophages and of osteoclasts. Preferably the animal is a mouse deficient in both GM-CSF and G-CSF, in GM-CSF and CSF-1, or in both G-CSF and CSF-1. Cell lines, such as bone marrow stromal cell lines, derived from the novel animals described herein are also within the scope of this invention. According to a second aspect, the novel animals of the invention, especially mice, provide a convenient model system for the study of disease. In one embodiment, this aspect of the invention provides a model system for the syndrome of alveolar proteinosis, both of the congenital form and the adult form, in which potential methods for treatment of this condition can be tested. In an alternative embodiment, this aspect of the invention provides a model system for the study of infectious diseases, especially bacterial infections of the lungs. In particular, this model system is useful for the study of opportunistic infeσtions of the type to which immunocompromised or immunodefiσient individuals are prone, and also of infeσtions whiσh are intractable to currently- available therapies, including antibiotic treatment. Immunocompromised individuals include persons suffering from cancer, especially those undergoing chemotherapy and/or radiotherapy, persons suffering from leukaemias, transplant recipients undergoing immunosuppressive therapy, and persons with autoimmune diseases undergoing immunosuppressive therapy. A particularly important group of individuals prone to opportunistic infections are those suffering from acquired immunodefiσienσy syndrome (AIDS) . The animals of the invention are expeσted to be useful for the study not only of bacterial and viral infections, but also infections with fungi and myσoplasma. Organisms suitable for study in the model system of the invention inσlude, but are not limited to. Lister ia, inσluding Listeria monocytogenes, Myco-bacteria, inσluding Mycobacterium tuberculosis, -Myco-baσteriu-m intracellulare, Mycobacterium avium, Mycobacterium bovis and atypical Mycobacteria; Pseudomonas speσies, inσluding Pseudomonas aeruginosa, Enterobacteriaceae, including Escherichia coli, Salmonella species, Klebsiella species, including Klebsiella pneumoniae and Klebsiella oxytoca; Pneumocystis carinii; Histoplasma, including Histoplasma capsulatum; Cryptococcus , including Cryptococcus neoformans; Pasteurella, including Pasteurella pestis and Pasteurella pseudotuberculosis (now known as Yersinia pestis and Yersinia pseudotuberculosis respectively) , and Pasteurella multocida (also known as Pasteurella septica); and Mycoplasma, including - coplas-ma pneumoniae. According to a third aspect of the invention, there is provided a method of treatment of pulmonary infection comprising the step of administering to a subject in need of such treatment an effective amount of GM-CSF or of G-CSF. Preferably the GM-CSF or G-CSF can be administered locally to the lung. This may be achieved by means of aerosols or nebulisers, for example ultrasonically nebulised formulations. Suitable carriers and excipients are known in the art. In intensive care situations, the CSF may be administered via an endotracheal tube. Optionally the GM-CSF or G-CSF may be administered as adjunctive therapy, for example concurrently with other known treatments for the particular condition. This aspect of the invention also provides a method of treatment of alveolar proteinosis or of pulmonary infection, comprising the step of administering to a subject in need of suσh treatment an effeσtive amount of GM-CSF. Where the GM-CSF or G-CSF is administered systemically, for example intravenously or subcutaneously, it is contemplated that dose ranges comparable to those known for use to stimulate granulopoiesis in patients undergoing cancer chemotherapy are suitable. Where GM-CSF or G-CSF is to be applied regionally to the lung, it is contemplated that the dose range will be from 0.1 μg/kg body weight to 20 μg/kg body weight. The person skilled in the art will readily be able to determine suitable dose ranges by normal trial and error experimentation. In particular, the acceptable degree of toxicity at high doses will depend on the condition to be treated. Compositions for administration of GM-CSF or of G-CSF to the lung are also within the scope of the invention. As will be discussed in detail below, we have surprisingly found that mice in which GM-CSF expression is disrupted are haematologiσally essentially normal, indiσating that GM-CSF is not by itself required for development and maturation of granuloσytes and monoσytes/macrophages, at least in a steady-state situation. However, the increased susceptibility of the GM-CSF deficient miσe to infection indicates that GM-CSF is required for "emergenσy" granuloσyte and maσrophage development. Similarly, miσe in which G-CSF expression is disrupted are neutropaenic, but have essentially normal levels of monoσytes/macrophages. Thus at least one other factor must be involved in steady state haemopoiesis, and the novel animals of the invention σan be used to identify and isolate suσh factors. Thus in a further aspect the invention provides a factor which is involved in regulation of steady-state haematopoiesis, and which is present in animals in which expression of GM-CSF or G-CSF is disrupted. Preferably the factor is also present in animals in which expression of both GM-CSF and G-CSF is disrupted, or in which expression of both GM-CSF and CSF-1 is disrupted. As is well known in the art, such haematopoietic growth factors in miσe have a high degree of homology with the σorresponding faσtors in humans, and this homology is suffiσient to enable a gene enσoding a murine factor to be used as a probe for the isolation of the corresponding human factor. Even if the degree of homology is relatively low, iterative screening at low stringency can be used. Therefore this aspect of the invention also provides a gene enσoding a faσtor involved in regulation of steady-state haematopoiesis, and which is present in animals in which expression of GM-CSF or G-CSF is disrupted, which can be used for isolation of the corresponding gene. Preferably the gene from the animal has at least 30% homology to the human gene, more preferably at least 50% homology, and even more preferably at least 90% homology. For treatment of individuals with alveolar proteinosis, including congenital alveolar proteinosis, gene therapy may be the most appropriate course. Methods for suσh gene therapy are known in the art, given that the identity of the defeσtive gene is known and that the appropriate DNA has been isolated. In a particularly preferred form, it is contemplated that intravenous administration of liposomal formulations of cDNA encoding GM-CSF will be used, as desσribed for example by N. Zhu, D. Liggitt and R. Debs et al, Sσienσe, 1993 261 209: "Systemiσ Gene Expression After Intravenous DNA Delivery Into Adult Miσe", the contents of which are herein incorporated by reference. Since it is evident from our results that genetically-determined deficienσy of a σolony-stimulating factor leads to increased susceptibility to infections, especially Gram-negative pneumonias, the invention also provides a method of diagnosis of a colony-stimulating factor deficiency, comprising the step of testing a tissue or cell sample from a subject suspected of suffering from such a deficiency for the absence of the gene encoding said factor. Preferably the colony-stimulating faσtor is GM-CSF, but G-CSF and M-CSF are also inσluded within the sσope of the invention. The test may suitably be σarried out using peripheral blood lymphocytes, but may also use tissue obtained by biopsy, for example from lung. A test may be σarried out using methods whiσh are known per se, such as polymerase chain reaction, or reaction with a probe labelled with a detectable marker, for example using in situ hybridisation. In a sixth aspect, the invention provides targeting constructs for disruption of the genes encoding GM-CSF and G-CSF respectively, as described herein. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows the scheme used for generation of GM-CSF deficient mice, and the strategy for disruption of GM-CSF gene, showing the intact GM-CSF gene with 4 exons (1,2,3&4), location of restriction enzyme sites (E=EcoRI, B=BgIll, SC=ScaI, SM=≤taaI, X=-X-mnI, P=P-=rtI, H=H±ndIII, S→→=Sall) , probe A (external to construct, diagnostic for targeted disruption) and probe B (corresponding to deleted sequences) and sites of PCR primer hybridisation (a=Edl20, b=Edl21, c=NEB#1224, see text) . In the disrupted allele, exons 1 and 2 and intron 1 are deleted, replaced by the E. coli lac-z gene, human β-globin 3' untranslated and polyA addition sequences (βG) and PG -neo (see text) . Figure 2 illustrates how deletion of GM-CSF exons 1-2 results in lack of GM-CSF immunoreaσtivity and bioaσtivity in spleen σonditioned media. Southern blot of Bglll digested tail DNA from PCR-genotyped GM+/+ and -/- miσe probed first with probe A (see Figure 1A) , confirming that deleted exons are present only in wild-type mouse, then reprobed without washing with probe B, confirming that the -/- mouse is homozygous for the disrupted GM-CSF allele and lacks the deleted sequences. Levels of immunoreactive (panel B) and bioaσtive (panel C) GM-CSF (solid columns) and bioactive IL-3 (open columns) in media conditioned by conσanavalin-A and IL-2 stimulated splenoσytes are shown for individual GM+/+ and GM-/- mice. In panel C, shaded column shows GM-CSF bioactivity after neutralisation with an anti-GM-CSF antibody. Figure 3 shows typical appearances of lung histopathology in GM-CSF deficient mice: A. Normal C57B1/6 lung, central region (13 week, H&E X40) B&C. GM-/- lung with moderate (B) and extensive (C) lymphoid hyperplasia around central and peripheral vessels (11 week, H&E X40) D. Detail of alveoli in GM-/- lung with large foamy macrophages, neutrophils and eosinophilic alveolar debris (7 week, H&E X400) E-H. Immunoperoxidase staining of perivasσular monbnuclear cells in GM-/- mouse lung (16 week, X200) with primary antibodies [specificity] : E, PBS [negative control]; F, RA3-6B2 [B220]; G, GK1.5 [CD4]; H, 53.6-7 [CD8] (same nodule in each panel) I-K. Focus of infection with fungal element in GM-/- lung (16 week, X400): I, positive control for Grocott stain; J, 5-10 μm Grocott-positive fungal particles; , PAS-positive fungal particles in same location of contiguous section L-N. Bacterial infeσtions in GM-/- lungs: L, Gram stain control with Gram-positive and Gram- negative bacilli; M, Gram-positive coccobacilli in pneumonic σonsolidated area (7 week, X400); N, . purulent acute Pasteurella pneumotropica lobar pneumonia in mouse dying at 4 weeks of age (H&E, X400) O-Q. Features of 24 week GM-/- lung: granular retractile PAS-positive homogenous eosinophilc material in contiguous alveoli (O, H&E X400; P, PAS X4 0); Q, emphysematous area (arrowed) with persistent peribronchovasσular lymphoid hyperplasia. Figure 4 shows the ultrastruσtural appearanσe of lungs from GM-CSF defiσient miσe. Eleσtron miσrosσopiσ sections of 24 week old GM-/- lung (same mouse as Figures 30-Q) . Solid bars indicate lμm. A. Type II surfactant-produσing alveolar σell with σharaσteristiσ intracytoplasmic lamellar bodies. The adjaσent alveolus σontains Type-C lamellar body. B. Numerous intra-alveolar Type-C lamellar bodies with charaσteristiσ "onion" appearance. C. Intra-alveolar macrophage with phagosomes σontaining "onion" structures resembling Type-C lamellar bodies. Figure 5a shows the screening strategy used to distinguish between wild-type and disrupted G-CSF alleles by genomic Southern analysis of Xbal digests of DNA. Hatσhed regions represent genomiσ sequenσes flanking the G-CSF gene. Black regions represent the exons of the G-CSF gene, and βG represents 3' untranslated sequences and polyA addition motif from the human β-globin gene. Figure 5b illustrates the targeting construct, designated pKOGCSF3b used to generate the ES cell line 5.4 from which the G-CSF defiσient animals were derived. Figure 6 shows Southern blot analysis of the ES cell line 5.4, from which founding G-CSF+/- chimeras were generated. The probe used in the left hand panel hybridizes with a region outside the targeting vector, and is diagnostic for homologous integration of the targeting vector at one G-CSF allele. The probe for β-galactosidase, used in the right-hand panel, hybridises exclusively with a region within the disrupted allele. Figure 7 shows the PCR-based screening strategy for the disrupted G-CSF allele. The primers are described in the text. Figure 8 shows PCR analysis of DNA from tail tissue of G-CSF +/- chimeras and their progeny. Figure 9 shows pups born from matings of heterozygous G-CSF+/- parents. Figure 10 shows PCR analysis of tail tisuse DNA from G-CSF -/+ σhimeras and their progeny, demonstrating germline transmission. Figure 11 shows results of assays on σonditioned media from organs of G-/-, GM-/- and wild-type mice. Figure 12 shows that G-/- mice are unable to produce G-CSF. Results of conditioned media from organs of G+/+ (wild-type) miσe are σompared with those of G-/- and GM-/- miσe. DETAILED DESCRIPTION OF THE INVENTION The invention will now be desσribed by way of referenσe only to the following non-limiting examples, and to the figures. Abbreviations The abbreviations used herein are as follows: CSF σolony-stimulating faσtor G-CSF granuloσyte σolony-stimulating faσtor GM-CSF granuloσyte-macrophage σolony- stimulating factor M-CSF macrophage colony-stimulating faσtor ES cells embryonic stem cells IL interleukin PCR polymerase σhain reaction Taq polymerase Thermus aguaticuε DNA polymerase ELISA enzyme-linked immunoadsorbent assay H&E haematoxylin and eosin stain PAS Periodic acid-Sσhiff stain SCM spleen-σell conditioned medium/media SCF stem cell factor G418 Genetiσin (Gibco, Grand Island, NY) bp base pairs Cell lines, vectors and antibodies Cell lines used herein are as follows: COS cells σell line of monkey origin able to support repliσation of veσtors σomprising the SV40 origin of repliσation. E14 ES cells derived from mice of strain 129/OLA (see Reference 17) FDC-P1 cell line which responds to GM- CSF and IL-3 32-D cell line which responds specifiσaly to IL-3 All these lines are well known in the art. Veσtors used herein are as follows: pIC20H Antibodies used herein are as follows: MP1-22E9 speσifiσ for GM-CSF MP1-31G6 second antibody used in ELISA RA3-6B2 specifiσ for B cells 187.1 specifiσ for B cells GK1.5 specifiσ for T helper cells 59.6-7 specifiσ for T suppressor cells 53-7.8 specific for pan T cell marker MATERIALS AND METHODS Statistics Data are given as mean ± standard deviations. To test for statistically significant differences, the unpaired Student's t-test and Chi-squared test were used. Generation of targeted ES cell colonies and chimeric mice In their general aspects, the methods employed are known per se. Methods for isolation and injection of mouse blastocysts, and implantation into host females for generation of transgenic mice, are extensively reviewed in the volume "Manipulating the Mouse Embryo - A Laboratory Manual" by B. Hogan, F. Costantini and E. Lacy (Cold Spring Harbor Laboratory, 1986) . Example 1 GM-CSF targeting vector and isolation of targeted ES cell clones. The GM-CSF targeting veσtor, illustrated in Figure 1 contained from 5' to 3 ' in plasmid pIC20H, approximately 900 bp of the GM-CSF promoter (Rsal-Scal) (13,14), the E. coli lac-z gene modified at the 5' end, an approximately 700 bp fragment of the 3' untranslated region and polyA addition motif from the human β-globin gene (EσoRI-AccI) , the PGK-neo selectable marker (15), and approximately 10 kb of GM-CSF genomic sequence from a previously isolated lambda clone (14) . The targeting vector was constructed to delete GM-CSF exons 1 and 2 and intron 1 between Seal and S-mal sites beσause in previous studies, σDNAs with this region deleted produσed no GM-CSF aσtivity when over expressed in COS cells (16) . The vector was linearized at a Sail site in the pIC20H polylinker prior to electroporation into E14 embryonal stem (ES) cells derived from mice of the strain 129/OLA (17), which were maintained and subsequently selected in medium σontaining the antibiotic G 18, as previously described (18) . After 8 days of G418 (Geneticin; Gibco) seleσtion, individual G418-resistant σolonies were σloned and replated. The polymerase chain reaction (PCR) was used to screen DNA from each ES cell colony for integration of a targeting vector by homologous recombination. The PCR primers were: "a" 5 • -CCAGCCTCAGAGACCCAGGTATCC-3 ■ , corresponding to sequence 5' of the Rsa∑ site in the GM-CSF promoter; "b" 5' -GTTAGAGACGACTTCTACCTCTTC-3 ' , corresponding to sequence in exon 2 of the GM-CSF gene in the region deleted by targeted construct integration; and "σ" a M13 (-47) 24mer sequencing primer (New England Biolabs, Beverly, MA, #1224), corresponding to the 5' region of the E. coli lac-z gene. These are illustrated in Figure l. in PCR reaction mixtures, primers "a" and "b" generate a 1.2 kb product from wild-type DNA, and "a" and "σ" a 1.0 kb product from DNA containing a σorreσtly integrated targeted σonstruct. PCR reaction mixtures (20μl) contained approximately 250ng DNA, 67mM Tris-HCl (pH 8.8), 16.6 mM (NH 4 ) 2 S0 4 , 0.45% Triton X-100, 200μg/ml gelatin, 1.5 mM MgCl 2 , 250 μM of each deoxynucleoside triphosphate, 12.5ng of each primer and 1.5 D of Taq polymerase. Following initial denaturation (95°C [150s]), 40 amplifiσation σycles were performed (95°C [50s], 60°C [50s], 72°C [60s]). The structure of targeted alleles identified by PCR was confirmed by Southern blot analysis of DNA from tail tissue of mice homozygous for the disrupted GM-CSF allele, which were generated as desσribed in Example 9 below. BfirllI-digested DNA was probed with a radiolabelled DNA fragment σorresponding to GM-CSF genomic sequenσes whiσh were deleted from the targeting σonstruct (probe A, Figure 1, Pstl-Ps l fragment) to verify that these sequenσes were absent from the presumptive GM-CSF homozygous null mice, and reprobed with a probe B (Figure 1) corresponding to sequences lying outside the targeting construσt (the BglII-JQnnl genomiσ fragment 5' of the Rsal site in the GM-CSF promoter) . Example 2 Generation of Chimeric Mice. Two clonally independent ES σell lines (designated GM4 and GM6) with a targeted GM-CSF gene disruption were seleσted for injeσtion into C57BL/6 mouse blastoσysts. The resulting male σhimeras from both cell lines transmitted the disruptive mutation through the germline in matings with females from a C57BL/6 background, to generate heterozygous male and female progeny. These heterozygous progeny were interbred to generate mice homozygous for the disruptive mutation. GM-CSF genotypes of mice have been designated as follows: wild-type, GM+/+; heterozygous GM+/-; homozygous GM-/-. The GM-CSF status of mice was routinely assessed by PCR analysis of DNA from tail tissue of the mice. GM-/- mice were subsequently bred from GM-/- x GM-/- matings, and to generate similarly outbred 129/OLA x C57BL/6 GM+/+ control mice, GM+/+ mice were bred from first- and second- generation GM+/+ littermates. Mice were kept in a σonventional animal house. Except where stated, observations come from the GM4 lineage. Example 3 Verification of GM-CSF gene disruption To confirm the structure of the targeted allele in GM-/- mice. Southern blotting analysis was performed on Bgill-digested tail DNA from randomly-selected GM+/+ and GM-/- miσe which had been genotyped by PCR, using a probe corresponding to the exon 1 and 2 sequences deleted in the targeted GM-CSF gene. As expected, GM+/+ but not GM-/- tail DNA σontained a 2.3 kb speσies hybridizing with the exon 1-2 probe. GM-/- DNA contained the predicted 7.7 kb species.when hybridized with a probe σorresponding to sequenσes lying outside the targeting veσtor, as shown in Figure 2A. Example 4 Spleen cell-conditioned media and GM-CSF assays. Spleen cell-conditioned media were prepared as previously described (19), exσept that the splenocytes were stimulated with concanavalin-A (5μg/ml, Boehringer- Mannheim, Germany) and interleukin-2 (lOOϋ/ml, Amgen, Thousand Oaks, CA) . To assay immunoreactive GM-CSF, an ELISA was used with the antibodies MP1-22E9 and biotinylated MP1-31G6 (Pharmingen, San Diego, CA) with an avidin-biotinylated horseradish peroxidase (Dako, Copenhagen, Denmark) detection system with a sensitivity of 50 pg/ml. To assay bioactive GM-CSF, the proliferative response of FDC-P1 cells, measured by 3 H-thymidine inσorporation, was used, adjusting for interleukin-3 (IL-3) bioaσtivity on 32-D cells, using methods previously described (20) . The MP1-22E9 neutralising antibody was used to confirm the specificity of the putative GM-CSF bioactivity. Standards used were recombinant murine GM-CSF (Sσhering-Plough, Kenilworth, NJ) and IL-3 (10 7 U/mg, Boehringer-Mannheim, Germany) . To confirm that tissues from GM-/- mice lacked GM-CSF, spleen cell-conditioned media (SCM) made from GM+/+ and GM-/- splenocytes were assayed for immunoreaσtive and bioactive GM-CSF. using a GM-CSF ELISA, no immunoreaσtive GM-CSF was deteσted in SCM from GM-/- splenoσytes while SCM from by GM+/+ splenoσytes contained more than 2700 pg/ml of GM-CSF. These results are summarized in Figure 2B. To assay for bioactive GM-CSF, the proliferative response of FDC-Pl cells, which respond to GM-CSF and IL-3, was assayed in parallel to that of 32-D cells, which respond only to IL-3. There was no detectable bioactive GM-CSF in SCM from GM-/- splenocytes, whereas GM+/+ SCM contained more than lOQpg/ml bioactive GM-CSF whiσh was at least 95% neutralised by an anti-GM-CSF antibody. To confirm the potency of these SCM, all were shown to contain bioaσtive IL-3, although SCM from GM-/- miσe contained less IL-3 than did SCM from control mice (GM-/-, 16+2 ϋ/ml, n=4; GM+/+, 49.+20 D/ml, n=4; p<0.01). The inability of GM-/- tissues to produσe GM-CSF in vitro was confirmed by studies on muscle and kidney conditioned media, using microwell assays of FDC-Pl σells (3). Example 5 Viability and fertility From initial matings of GM+/- mice, litters of 10+3 pups (n=8, GM6) resulted, with the genotypes GM+/+, +/- and -/- represented in approximately Mendelian ratios amongst live births surviving to weaning, indicating that there was no selective fetal or neonatal loss of GM-/- pups. Survival of miσe from initial litters was normal amongst GM-/- pups (>91%, n=35) compared to their GM+/+ littermates (>88%, n=17), with a median follow-up for GM-/- mice of 220 days [range 0-334] days and for GM+/+ mice of 209 days [range 0-313] days; median survival has not been attained. Post-mortem examination of the two dead GM-/- adults in this cohort indicated that one, which died at 153 days, had lymphoid leukaemia and the other, which died at 167 days, had hepatitis; both displayed the charaσteristic GM-CSF deficienσy lung disease which is described in detail below. From initial matings of male and female GM-/- mice, litters of 9.+1 pups (n=5) resulted, indicating that GM-CSF defiσienσy did not grossly impair fertility or feσundity. Example 6 Haematological analysis of GM-CSF deficient mice Haemoglobin, total leukocyte and platelet estimates were performed on 1:4 dilutions of eye-bleed samples on a Sysmex-KlOOO automated σounter, and manual 100-cell leukoσyte differential counts were performed on May-Grunwald/Giemsa stained smears. Progenitor cells were assayed in semisolid agar cultures of bone marrow, spleen or peritoneal cells by a standard method, as previously described (19,21). Colony formation was stimulated by purified recombinant bacterially-synthesized growth faσtors at the following final concentrations: human G-CSF [10 ng/ml], murine GM-CSF [10 ng/ml], murine IL-3 [10 ng/ml], murine M-CSF (CSF-1) [10 ng/ml] rat stem cell factor [100 ng/ml], murine IL-6 [500 ng/ml], and spleen cell-conditioned medium (10%). Colonies were typed on stained whole-plate preparations as previously described (21) . The haematological parameters of peripheral blood of 6-7 weeks GM-/- mice showed no significant difference from those of blood of GM+/+ littermates, as illustrated in Table 1. Table 1 Haematological Analysis of GM-CSF - deficient mice GM+/+ GM-/- Haemoglobin (g/1) 162+7 163+5 total leukocytes (xlO 9 cells/1) 5.9+1.0 7.4+_2.4 neutrophils (xlO 9 σells/1) 1.1+0.3 1.2+.0.6 lymphocytes (xlO 9 cells/1) 4.7.+1.1 6.0+2.0 monoσytes (xlO 9 σells/1) 0.12^0.10 0.13±0.13 eosinophils (xlO 9 σells/1) 0.09+0.06 0.13+0.13 platelets (xlO 9 σells/1) 838+.105 822+.109 10 miσe in eaσh group were tested Results are expressed as mean +_ S.D. GM-/- miσe tended to have greater variation in their granuloσyte levels, as illustrated by the granuloσyte levels of 5-7 week miσe: GM-/- 1.7+1.5 x 10 9 /1 [n=33, range 0.2-6.6]; GM+/+ 1.3+O.7 x 10 9 /1 [n=15, range 0.29-3.1], with 24% of GM-/- miσe having neutrophils greater than 2 x 10 9 /1 σompared to 15% of GM+/+. Spleens of GM-/- miσe showed inσreased variability in mass (e.g. spleen mass of 6 weeks miσe, n=6/group: GM+/+ 106+.9 [range 94-120] mg; GM-/-, 114+42 [range 64-191] mg) . Haematopoiesis was evaluated in five pairs of 6-8 week GM+/+ and -/- miσe. Femoral σellularity was equivalent (GM+/+ 34.0+.5.3 x 10 6 , GM-/- 27.447.0 x 10 6 σells/femur, n=3) and the myeloid:erythroid ratios were equivalent (20+2 and 17+6 % erythroid σells respectively) . The results of analysis of marrow progenitor cells responsive to various stimuli, summarized in Table 2, revealed no major difference in total progenitor cell frequency, and colony subtyping indicated no differenσes in frequenσies of granuloσyte, granuloσyte-macrophage, macrophage, eosinophil, megakaryocyte, erythroid and blast marrow progenitor cells. To assess the role of GM-CSF in the phenomenon of "spontaneous" in vitro colony formation, crowded unstimulated cultures of up to 2 x 10 5 GM-/- marrow cells/ml were established; colony formation was somewhat reduced, indiσating that "spontaneous" σolony formation is not solely dependent on in vitro GM-CSF production. Table 2 Haematopoietiσ progenitor cells in GM-CSF deficient miσe Total σolonies (mean ± S.D. Cells σultured (n) Stimulus GM+/+ GM-/- 25,000 GM-CSF 59+12 51+19 bone marrow G-CSF 19+3 15+7 (5) M-CSF 64+16 59+25 IL-3 68+12 68+19 SCF 29+3 22+13 IL-6 18+8 18+10 SCF + GM-CSF 66+.12 63±26 200,000 Saline 79+62 39+44 bone marrow (5) 100,000 GM-CSF 3+4 8+2 spleen SCF 0 4+2* (3) SCF + GM-CSF 3+1 20+2* SCM 4+3 18+2* (n) indiσates the number of individual miσe studied * indicates p<0.001. Cultures were stimulated by: granulocyte-maσrophage-CSF (GM-CSF), granuloσyte-CSF (G-CSF), CSF-I (M-CSF), interleukin-3 (IL-3), stem cell factor (SCF), interleukin-6 (IL-6), spleen cell-conditioned medium (SCM), or a combination of these. Genotype is indiσated as wild-type (GM+/+) or GM-CSF defiσient (GM-/-) . The spleen masses for these groups of miσe were: GM+/+, 64+_8 mg; GM-/-, 114+.22 mg (p<0.001). Analysis of spleniσ haematopoiesis showed a 3 to 6 fold inσrease in frequenσy of progenitor σells in GM-/- iσe, and as the GM-/- spleens were signifiσantly larger, this represented an absolute inσrease in number of spleniσ progenitor cells (Table 2) . Peritoneal washings recovered 6.0+1.4 x 10 6 and 5.1+1.4 x 10 6 cells from GM+/+ and GM-/- miσe respeσtively; these washings σomprised 65% maσrophage in GM+/+ and 63% maσrophages in GM-/- miσe. Example 7 Histological examination of GM-CSF deficient mice and characterisation of pulmonary disease Formalin-fixed paraffin-embedded sections of mouse organs were stained using standard techniques with haematoxylin and eosin (H&E) , and selected seσtions were stained with the Grocott methenamine silver and periodic- acid-Schiff (PAS) stains, and Ziehl-Neelsen and ade-Fite aσid fast stains. Immunoperoxidase staining of lung tissue was performed using a standard method (22) on 4 μm frozen seσtions, with the following antibodies: RA3-6B2 [speσifiσ for B220] (23), 187.1 [speσifiσ for K light chain] (24), GK1.5 [specifiσ for CD4] (25), 53.6-7 [specifiσ for CD8] (26), and 53-7.8 [speσifiσ for CD5] (Pharmingen, San Diego, CA) . For eleσtron miσrosσopy, random strips of fresh lung tissue were immersion-fixed in 2.5% glutaraldehyde in 1% sodium σaσodylate buffer (pH 7.4), postfixed in 2% aqueous osmium tetroxide, and embedded in Araldite-Epon resin using standard teσhniques. Thin seσtions were stained with alkaline lead σitrate and uranyl aσeta e, and viewed in a Jeol 1200EX eleσtron miσrosσope. Histologiσal seσtions from GM-/- mice aged 1 day to 24 weeks and age-matched GM+/+ σontrols of age were reviewed. No major differences between GM+/+ and GM-/- were evident in haematopoietic tissues; marrow cellularity was normal and some GM-/- spleens were enlarged with hyperplasia of both red and white pulp. Whilst at birth the lungs of GM-/- and GM+/+ animals were indistinguishable, within the first 3 weeks of post-natal development striking abnormalities were evident in the lungs of GM-/- mice. Individual lungs from GM-/- mice consistently showed foσal aggregates of lymphoid cells in peribronchial and perivasσular areas, but little infiltration of alveolar septa; typical results are shown in Figure 3A-C. Immunoperoxidase staining of 12-16 week GM-/- lungs showed these cells to be predominantly B-lymphocytes on the basis of positive staining for B220 and K-light chain. About 20% of lymphocytes were T-cells, predominantly of the CD4 + type (Figure 3E-H) . The lymphoid foci were particularly marked around large hilar vessels, occasionally assuming a follicular organization, but the cells exhibited little mitotiσ aσtivity. The foσi characteristically extended peripherally around small bronσhioles and arterioles. Foσal σonsolidation was prevalent, and σonsisted of an intensely eosinophiliσ alveolar exudate containing numerous mature and fragmented neutrophils and macrophages (e.g Figure 3D,M,N) . Associated bronσhioles σontained purulent exudate. In almost every GM-/- mouse of up to 6 weeks of age, aσute inflammatory areas were found in the distal tips of the pulmonary lobes. Lobar σonsolidation was frequently observed (Figure 3M&N) . In lungs of older miσe (6-12 weeks), the lymphoid hyperplasia predominated; alveoli σontained large foamy macrophages and granular debris, and foci of aσute inflammation, comprising aggregates of up to 50 neutrophils and mononuclear cells, were sometimes seen (Figure 3D) . Granular, eosinophilic, PAS-positive material within alveoli was present in all lungs examined (e.g. Figure 3D&K), apparently acσumulating and beσoming σonfluent in some alveoli by as early as 3 weeks. This material was present until at least 6 months of age, and in some areas of 12-24 week GM-/- lungs contiguous alveoli σontaining this material resembled the appearanσes of alveolar proteinosis (Figure 30&P) . Ultrastruσturally, surfaσtant-produσing type-ll alveolar cells were readily identified by their characteristic cytoplasmiσ lamellar bodies (Figure 4A) ; the alveolar debris inσluded numerous type-C lamellar bodies (Figure 4B) , and these onion-like bodies were seen within phagosomes of intra-alveolar maσrophages (Figure 4C) . Peripherally, the alveolar spaces of lungs from older mice (24 weeks) were large, suggesting an emphysematous process (Figure 3Q) . One 4 week-old GM-/- mouse died with florid lobar pneumonia (Figure 3N) from which Pasteurella pneumotropica was isolated, corresponding to Gram-negative organisms evident in lung sections. A survey of GM-/- lungs with Groσott and PAS stains identified foσi of 5-10 μm diameter fungal elements in 3/15 GM-/- lungs but 0/7 GM+/+ lungs (e.g. Figure 3I-K) . Surveys of seσtions with Gram stain identified large numbers of Gram-positive σoσcobacilli in one pneumonic area (Figure 3L&M) . No mycobaσterial infeσtions were evident with Ziehl-Neelsen and Wade-Fite stains. One 6 week-old GM-/- mouse had developed a chronic pulmonary abscess with an organized wall lined by foamy maσrophages and containing neutrophil-rich pus. Example 8 GM-CSF Deficient Mice Can Be Used to Test Host Response to Infection Ten wild-type and ten GM-CSF deficient mice were challenged by intravenous injection with Lister ia monocytogenes, at a dose of 5 x 10 3 colony forming units per mouse. Haematological parameters and bacterial counts in the liver and spleen of mice sacrifiσed at day 1 and day 5 after infeσtion are summarised in Table 3. Table 3 Haematological Response to Listeria Infection Haematological Before injection Day 1 Day 5 Parameter GM+/+ (10) GM-/- (10) GM+/+ (10) GM-/- (10) GM+/+ (10) GM-/- (10) Haemoglobin g/L 162+.7 163±5 148±9 152+.13 134+.6 127+.6 Platelets xl0 9 /L 838±105 8224:109 750±96 710+.99 776+375 352+.340 Listeria organism counts (log mean ± SD) Day 1 Day 5 GM+/+ GM-/- GM+/+ GM-/- (5) (5) (5) (5) Spleen per organ 5.00+.0.48 5.11±0.35 2.65+.0.10 5.98±1.44 per gm 6.05±0.45 6.11±0.40 3.26+.0.18 6.76±1.66 Liver per organ 4.17i0.51 5.02+.0.40 2.04+.0.41 6.15+.1.92 per gm 4.24+_0.51 5.03+.0.46 1.96+.0.39 6.16±2.00 Results for the haematological parameters are presented as mean +. standard deviation, while those for organism counts are presented as log mean +_ standard deviation. The figures in brackets represent the number of mice in eaσh group. On Day 5, 2 GM-/- miσe were dead, with organism counts of greater than 10 8 per organ for spleen or liver. The surviving GM-/- animals had 5.66 +_ 0.95 organisms g/spleen and 4.81 +.1.07 organisms/liver, which was still much higher than the counts for GM+/+. Haematologically, the GM-/- mice showed a perturbed response, with an impairment of neutrophil mobilisation on Day 1 and neutrophil produσtion on Day 5, despite the presence of established Listeria infection. The GM-/- miσe were unable to control the Listeria infection as well as could their littermate controls, showing a higher baσterial load in the liver on Day 1, and a higher baσterial load in both liver and spleen on Day 5. Thus the GM-CSF defiσient miσe do constitute a useful model for testing the host response to infection. Example 9 GM-CSF Deficient Mice Are A Suitable Model For Vulnerability To Infection Blood counts on age-matched 3 week-old GM-/- miσe reared under conventional conditions were σompared with those from miσe reared in a miσroisolation ("speσific pathogen-free"; SPF) environment. The results are summarised in Table 4. Table 4 Comparison between GM-/- Mice Reared in Conventional and SPF Environments Parameters SPF Conventional p Value (t test) Whole body mass (g) 13.44:0.8 11.9±2.1 NS liver mass ( g) 576±63 5764:95 NS (mg) 72+26 95±8 <0.1 (NS) 0.53+.0.16 0.874:0.16 <0.02 135+.6 148;f9 <0.05 CA Total White Cells xl0 9 /L 7.7+2.2 8.9±3.4 NS H Neutrophil 0.99±0.70 2.98+2.02 (NS) <0.1 Lymphocytes 5.55+2.12 5.23±1.01 NS Monocytes 0.13+0.06 0.69+.0.50 <0.05 S&> Eosinophils O±O 0+.0 NS Platelets xl0 9 /L 763+91 804+16 NS NS = not signifiσant The mice from the microisolation environment had lower neutrophil and monoσyte levels, strongly suggesting that the miσe from the σonventional environment had been exposed to a range of infectious agents during their first three weeks of life. Despite the lack of statistical significance as assessed by Student T-Tests, there is a marked indication that the mice from the microisolation environment had lower neutrophil levels and a profile suggestive of lesser degree of infection. Thus there is strong evidenσe for an environmental influenσe on these parameters. Discussion Sinσe the aσtions of various haematopoietic regulators on target cells appear to overlap, it is possible that individual regulators might be wholly or partially redundant (27) . This proposition is most direσtly assessed by analysis of mice deficient in individual regulators or σombinations of regulators. Our analysis of GM-CSF deficient mice up to 3 months of age found that there was no perturbation of major haematopoietic populations in marrow or blood. There are two obvious ways in which to interpret this observation: either GM-CSF may not be a pivotally important regulator of normal haematopoiesis, or alternatively, GM-CSF may σontribute to the maintenance of steady-state haematopoiesis, but in its absence other haematopoietic regulators are able to replaσe the role normally σarried out by this regulator. This latter possibility would be further supported if elevated levels of compensatory regulators were demonstrated in the GM-CSF deficient mice. Spleniσ progenitor cell levels were increased in GM-CSF deficient miσe, but this may in part refleσt subσliniσal pulmonary infection in the animals; it will be important to assess to what extent the pulmonary disease process is impacting on "steady-state" haematopoiesis, particularly in the spleen. The possibility that GM-CSF is a wholly redundant molecule can clearly be discounted in the light of our observation that all GM-CSF deficient miσe show abnormal lung development. Our initial studies have not identified the nature of the intrinsiσ pulmonary defeσt. However, the same pathology is not seen in control animals, strongly suggesting that it is due to GM-CSF deficiency. A prominent pathological feature is granular eosinophilic intra-alveolar material, whiσh sometimes beσomes confluent. This may be a local product, suσh as pulmonary surfactant phospholipid and protein, either produced in excess or σleared too slowly due to a funσtional defeσt of maσrophages. The presenσe of numerous type-C lamellar bodies within alveoli and maσrophages is consistent with the accumulation of surfactant components (28) . In some areas, the histological appearance of lungs from GM-CSF deficient mice bears a striking resemblance to some forms of alveolar proteinosis, a heterogeneous group of congenital and acquired lung disorders characterised by the intra-alveolar accumulation of surfactant protein, and often compliσated by infeσtion (28-31) . The roles of GM-CSF or of σells functionally activated by GM-CSF in the produσtion of surfaσtant by type II alveolar σells and on surfaσtant clearance have not been studied. Whilst clearance of mucinous seσretions in larger airways may also be defeσtive, retained seσretions are not prominent in the lungs of younger GM-CSF-/- miσe, whiσh already have exσessive alveolar material. A prominent feature of the lung pathology of GM-CSF defiσient miσe is the presenσe of infection with a range of opportunistic organisms, including both baσterial and fungal agents. Interestingly, infeσtion of immunocompromised CD4+ T-σell depleted mice with Pneumoσystis carinii results in peribronσhovascular lymphoid hyperplasia of similar appearances to that in GM-/- mice (32), suggesting that the lymphoid hyperplasia may be an aspeσt of the general pulmonary response to infeσtion. When infection ocσurs, the host response is usually adequate to prevent death, as only less than 0.5% of GM-/- mice have died from lung infection. However, the lymphoid hyperplasia, prevalent acute bacterial pneumonia, and subclinical multifocal fungal infection suggest that the host response to infection is defective. Pneumocystis carinii pneumonia is common in AIDS patients, frequently being the ultimate cause of death. The presence of large numbers of neutrophils and macrophages within GM-/- lungs indicates that inflammatory cells can still be localized in the lung in the absence of GM-CSF to aσtivate aσute and σhronic inflammatory proσesses within tissues, although the numerical and functional adequacy of the σells involved in this response has not been evaluated. Indeed, alveolar macrophages are particularly responsive to GM-CSF, and many cell types present in the lung (including epithelial cells) are capable of GM-CSF synthesis (33,34). It is possible, therefore, that a significant component of the intrinsic pulmonary defect is the absence of local GM-CSF-dependent activation of macrophages involved in either surfactant σlearanσe or infeσtion σontrol. We are testing the influenσe of environmental factors on the pulmonary manifestations of GM-CSF deficienσy by comparing GM-CSF deficient mice raised in conventional and gnotobiotic animal facilities. The prominent pulmonary pathology acσompanying absolute GM-CSF defiσienσy suggests that GM-CSF may be useful for treatment of lung disorders characterised by accumulation of alveolar material such as alveolar proteinosis, or by infection. Acquired forms of alveolar proteinosis may reflect a local relative deficienσy of GM-CSF. Amongst σongenital forms of alveolar proteinosis, there may be a human counterpart to murine GM-CSF deficienσy for whiσh GM-CSF replaσement therapy would be appropriate. There is σonsiderable evidenσe that GM-CSF σan be effective in treatment or prevention of bacterial and viral infeσtions, and may also have some role in resistance to parasite infection (34-38) . Example 10 G-CSF Targeting Vector And Isolation of Targeted ES Cell Clones The G-CSF targeting vector, illustrated in Figure 5, was designed to effeσt a disruption of the G-CSF gene (Tsuσhiya, M., Kaziro, Y. and Nagata, S.; Eur. J. Bioσhem., 1987 165 7-12) comprising a deletion of sequences between the Ncol site in exon 1, which encompasses the translational initiation codon ATG, and the BamHI site in exon 3. Sequences comprising the E. coli lac-z gene with a modification at the 5' end to facilitate cloning into a Ncol site, and the neomycin phosphotransferase gene driven by the phosphoglyσerate kinase (PGK) promoter, and with 3' untranslated sequenσes derived from the veσtor pMClΝeo were inserted at the site of this deletion. The construct, designated p OGCSF3b, comprised a hybrid vector baσkbone derived from the veσtors pBR322 and PSP73, from 5' to 3', approximately 1.1 kb of genomiσ sequence immediately 5 ' of the G-CSF protein coding sequence, including the G-CSF promoter (the Asp 700 - Ncol fragment), the E. coli lac-z and neomyσin phosphotransferase sequenσes set out above, and approximately 7 kb of genomiσ sequence commenσing at the BamHI site in exon 3 and limited at the 3 ' end by a BamHI site. This σonstruσt is illustrated in Figure 5b. In this figure the approximate sizes in kb of genomic sequences are indicated by the bars. The Ncol site labelled with the asterisk enσompasses the translation initiation site in exon 1 of the murine G-CSF gene. The BamHI site labelled with a σross lies in exon 3 of this gene. βG represents a 700 bp fragment of the 3' untranslated region and polyA addition motif from the human β-globin gene. The sequenσes in the neomyσin phosphotransferase expression σassette are derived from PGK-Neo (sequenσes 5' of the Ncol site) and pMClΝeo (sequenσes 3' of the Ncol site). The veσtor backbone is a hybrid of sequences derived from pBR322 and pSp73. The sequenσes from these two veσtors are joined in the targeting σonstruσt at the -Xmnl site in the Aaιp R gene to reσreate a funσtional Amp R gene. The origin of replication is derived from pBR322. The 3' end of the homologous genomic sequence in the construct is defined by a BamHI site in genomic sequences, although this site was ablated during construσtion of the targeting veσtor. Transformation and seleσtion of ES cells were carried out generally as described in Example 1. Polymerase chain reaction was used to screen DΝA from eaσh ES σell σolony for intergration of the targeting veσtor by homologous reσombination. The PCR primers were as desσribed below. Chimeriσ miσe were generated and maintained as desσribed in Example 2. Exσept where stated, the following observations were obtained using the 5.4 lineage. Example 11 Verification Of G-CSF Gene Disruption To confirm the structure the targeted allele in G-/- mice, Southern blotting analysis was carried out on genomic DΝA from ES σell lines or mouse tail tissues, which was prepared by standard techinques and digested with Xbal . Results are shown in Figure 6. This figure σonfirms the prediσted struσture of the disrupted G-CSF allele, using probes σorresponding to sequenσes both external to and internal to the construct. The probe corresponding to G-CSF genomic sequences lying outside those of the targeting construσt pKOGCSF3b was a 5 ' -Sacl-Bglll fragment. This probe was diagnostic for homologous integration at one G-CSF allele. DΝA from the ES σell line 5.4, whiσh as desσribed below was confirmed to contain a disrupted G-CSF gene, showed a 14 kb band corresponding to the wild-type allele, as well as a seσond larger band corresponding to the disrupted allele. The identity of this second band was confirmed by reprobing the Southern blot with a second probe corresponding to 3.2 kb of sequenσe from the E. coli lac-z gene, showing that only a band corresponding in size to that of the disrupted allele contained lac-z sequences. Thus incorporation of these sequences into genomic DNA at the disrupted G-CSF allele was confirmed, as well as the fact that only one copy of the targeting construct sequences was present in the genome of these ES cells. Example 12 PCR Analysis A PCR probe specific for the disrupted G-CSF allele was used to demonstrate that matings of heterozygous parents resulted in progeny which were homozyous for the disrupted G-CSF allele. These results are shown in Figure 7. G105 template DNA was shown to have the genotype G+/- by Southern analysis. The symbols -, + and ++ indiσate primer σoncentrations of 0.20 ng/20 μL reaction mixture, and 40 ng/20 μL reaction mixture. The primer sequenσes are: GL#2 5 ■ -TCC.ATG.ACA. C .GTG.GCC.ACC.AGA-3 ' ES#132 5' -CTG.CAA.GGC.GAT.TAA.GTT.GGG. AA-3 ' GL#4 S'-CGG.CCT.CTC.GTC.CTG.ACC.ATA.GTC-S' The PCR reaσtion mixtures were as described in Example 2, except that the σoncentration of MgCl 2 was 2.0 mM and 20 ng of each primer was used, and 35 amplification cyσles were performed, annealing at 62° for 50 seσond . When maximal sensitivity was required, PCRs to identify wild-type and disrupted alleles were performed separately. When DNA from tail tissue was sσreened, PCRs to diagnose wild-type and disrupted alleliσ status were σarried out in a single reaσtion mixture, whiσh σontained 40 mg of primer GL#2 and 20 ng of the other two primers. Primers GL#2 and GL#4 generate a 1.2 kb PCR produσt from template DNA σontaining a wild-type allele, while primers GL#2 and ES#132 generate a 1.1 kb PCR produσt from template DNA σontaining a disrupted GSF allele. Results of PCR analysis on the first litter resulting from mating G-CSF +/- parents are shown in Figure 8. The PCR pattern demonstrates that progeny homozygous for the disrupted G-CSF allele were produced. We have thus demonstrated germline transmission of the disrupted allele. We have also shown that animals bearing the disrupted allele are viable and fertile. Example 13 Cells From G-CSF Deficient Mice Are unable To Produce G-CSF An assay specifiσ for mouse G-CSF was devised and validated. This assay utilised BAF3 σells modified to express reσeptors for G-CSF. These σells are designated BAF3-GR. Control (untransformed) BAF3 σells, whiσh respond to Multi-CSF and also respond weakly to IL-2, were used as σontrols. Conditioned medium from thy us, lung, bladder, bone shaft and spleen were σompared with a σontrol preparation σontaining 1 mg/mL of purified G-CSF. These results are shown in Figure 11, and indiσate that the BAF3-GR σells respond speσifiσally to G-CSF, with a lower limit of sensitivity of 30 pg/ L. The results obtained with BAF3 cells show that neither Multi-CSF nor IL-2 is present in the conditioned medium from these organs. Conditioned media from thymus, lung, bladder, bone shaft and spleen were prepared from organs of G-CSF defiσient and wild-type animals, and assayed in the BAF3-GR test system. All of the σonditioned media from organs of wild-type mice contained titratable levels of bioactive G-CSF, whereas no bioactive G-CSF σould be deteσted in σonditioned media from organs of G-/- animals. The results are illustrated in Figure 12. In addition, assays of sera of G-/- and wild- type miσe were unable to deteσt G-CSF. With serum the lower limit of sensitivity is 120pg/ml. Example 14 Haematological Analysis of G-CSF Deficient Mice Haemoglobin, total leukocyte and platelet estimates were performed on samples from G-CSF deficient mice, as described in Example 6. The results are summarised in Table 5, and show that the G-CSF defiσient miσe (-/-) have a durable base line neutropaenia σompared to wild-type (+/+) or heterozygous (+/-) mice. However, in the G-CSF deficient miσe other parameters were within the normal range. Table 5 Haematological Parameters in G-CSF -/■ M ce Mice aged 3-4 weeks Genotype (n) G+/+ (31) G+/- (30) G-/- (18) Haemoglobin g/L 142+JL2 140+.13 140±15 Platelets xl0 9 /L 514+222 519+.199 532+198 Total White Cells xl0 9 /L 6.79±1.66 6.25+.2.09 5.48+.2.16 Neutrophils xl0 9 /L 0.63+.0.29 0.42+.0.27 0.17±0.12 Lymphocytes xl09/L 5.59+.1.84 5.45+2.05 5.04i2.07 Monocytes xl0 9 /L 0.27±0.19 0.22+.0.15 0.234:0.13 Eosinophils 0.14+0.12 0.13+0.13 0.10+0.10 Miσe aged 12-16 weeks G+/+ (5) G+/- (0) G-/- (7) Haemoglobin g/L 169±9 ND 169±18 ! Platelets xl0 9 /L 798+.134 802±125 Total White Cells xl0 9 /L 10.0±2.5 7.664:3.0 Neutrophils 0.574:0.19 0.20±0.12 Lymphocytes 9.10±2.37 7.24i2.94 Monocytes 0.284:0.19 0.174:0.05 Eosinophils 0.07+0.08 0.03+0.04 n = number of mice Results are expressed as mean +. s.d. Example 16 G-CSF Mice Constitute A Model Of Chronic Neutropaenia The durability of neutropaenia in the G-CSF deficient mice is evident from the data presented in Example 13. A model of chronic neutropaenia is useful to test new therapies applicable to diseases characterised by chronic neutropaenia, and to test the role of neutrophils in experimental models infeσtion, inflammation or malignancy, in a situation of relative neutrophil deficienσy. For example, a 154 day-old female G-/- mouse was killed because it appeared ill, and was found to have a severe endometritis accompanied by enlarged para-aortic lymph nodes, and enlargement of spleen, lungs, heart and liver. Histological examination confirmed pelvic inflammation and endometritis, as well as presence of large numbers of intensively eosinophilic, multinucleated macrophages in the alveoli of the lungs. This mouse had a severely abnormal blood profile (haemoglobin 108 g/L, total leukocyte count 29 x 10 9 /L, and platelet count 418 x 10 9 /L) , and 70% of the circulating leukocytes were monocytes. Endometritis is an unusual infection in mice, and we have not seen it in any other immunocompromised animal in the last twelve months. The infection was probably introduced during mating, and the deficiency of neutrophils and G-CSF probably contributed significantly to the vulnerability of the animal to this infection. The profound, excessive monocytosis seen in this animal during bacterial infection is very abnormal, and it appears that inability to make G-CSF had impaired its capacity to mount an appropriate granulocytic response to infeσtion. This monocytosis may indicate an attempt to compensate for the lack of neutrophils by generating monocytes and macrophgaes via the remaining intact mechanisms of haemopoiesis. Example 17 G-CSF Deficient Mice Are Vulnerable To Bacterial Infection G-CSF deficient and wild-type miσe were σhallenged with Listeria monocytogenes, administered by intravenous injeσtion at a dose of 5 x 10 3 σolony forming units per mouse, and haematological and bacterial load end points were examined at 1 hour, 1 day and 5 days after injeσtion. The results are summarised in Tables 6 and 7. EET Rule26 Table 6 Haematological Parameters in Mice Injected with Listeria Haematological Baseline lhr after Listeria Parameters +/+ G-/- +/+ G-/- (13) (13) (13) (13) 3.18±0.38 2.76±0.99 0.074:0.08 0.09±0.08 Eosinophils 0.04±0.10 0.044:0.06 0.06+.0.06 0.044:0.05 Table 6 (cont. ) Haematologiσal 1 Day After Listeria Injection 5 Days After Listeria parameter +/+ G-/- +/+ G-/- (13) (13) (8) (8) Haemoglobin g/L 157 ±8 155+4 140+.11 1344:8 Maσ + F4/80 + % ND ND 12 19 Maσ + Grl low % ND ND 13 19 Maσ + Gr " % 7 9 ND ND Figures in braσkets = number of miσe FACS = fluoresσenσe aσtivated σell sorter Table 7 Response of G-/- Mice to Listeria Infection Baσteria Load Wild-type (mouse no. ) Spleen Liver In Table 6 the bacterial counts (raw data) are shown for individual mice, analysed five days after injection of Listeria. G-CSF deficient mice do not have a readily mobilisable pool of neutrophils, as illustrated by the fact that their neutrophil counts are low 1 hour after Listeria infection compared to wild-type mice. Although their neutrophil levels do increase in absolute terms during the course of Listeria infection, this haematological response is markedly impaired compared to that of the wild-type controls, never attaining even the baseline level of the σontrol group. This impaired haematological response correlates with the generally higher bacterial loads observed in the liver and spleen of these mice 5 days after infection. Example 16 Production of Mice Deficient In Both GM-CSF and CSF-1 GM-CSF deficient mice (genotype GM-/-) and appropriately outbred GM+/+ controls were generated as described above. Initial GM-/- M-/- were generated by interbreeding GM+/- M+/+ and GM+/+ M+/- miσe (i.e. op/+) and selecting the GM+/- M+/- progeny for interbreeding. These matings generated the' various genotypes in appropriate ratios, including GM-/- M-/- and GM+/+ M-/- (i.e. op/op) . To generate additional GM-/- M-/- animals, GM-/-M+/- mice were mated. Example 17 Viability and Fertility of GM-/- M-/- Mice From initial matings of GM+/- M+/- x GM+/- M+/- iσe, litters of 1±2 pups (n=15) were born. The nine possible genotypes were represented in approximately the expeσted Mendelian ratios at weaning amongst 144 pups, as summarized in Table 8. Table 8 Ratio of Genotypes in Litters From Matings of Miσe Heterozygous for Both M-CSF and GM-CSF Null Mutations Genotype Expected ratio Observed GM M of 16 of 144 total "maleW +/+ +/+ 1 9 10 5 (50) +/+ +/- 2 18 16 6 (38) +/+ -/- 1 9 10 6 (60) +/- +/+ 2 18 19 11 (58) +/- +/- 4 36 28 16 (57) +/- -/- 2 18 15 9 (60) -/- +/+ 1 9 17 11 (65) -/- +/- 2 18 21 6 (29) -/- -/- 1 9 8 6 (75) Results from 144 genotyped progeny of 4 double- heterozygous breeding pairs. During this period, the following mice were not genotyped: one litter of 9 pups that died at 3 days, 2 GM?M-/- males, 2 GM-/-M? males, one GM?M? female. In particular, GM-/- M-/- mice were not signifiσantly under-represented relative to wild-type miσe, indiσating that GM-/- M-/- miσe were viable and there was no major fetal or neonatal loss, although amongst this genotype, male miσe were over-represented. Subsequently, GM-/- M+/- x GM-/- M+/- matings generated litters of whiσh 25/164 (15%) of pups were GM-/- M-/-; this was signifiσantly fewer than expeσted (p<0.05), and there was again a male preponderanσe (19/25) (p<0.1). GM-/- M-/- males were fertile; one suσh male mated with a GM-/- M+/- ΓUTESHEET Rule26 female has sired 5 litters of 5+3 pups. We have not bred from M-/- females regardless of their GM-CSF status, in view of the difficulties experienced by others. The Chi-squared test was used to test for differences amongst viability and fertility data. An unpaired t-test was used to test for statistically significant differenσes in hematological data. Kaplan-Meier survival curves were construσted to σompare survival data, and median survivals were tested for differenσe using the Mantel-Cox statistiσ. For survival data, miσe killed beσause of apparent illness were regarded as non-survivors. A p-value of <.0.05 was regarded as statistiσally signifiσant. Survival of GM-/- M-/- was σompared to that of all other toothless miσe (GM+/- M-/- and GM+/+ M-/-), and mice deficient only in GM-CSF (GM-/- M+/+) and wild-type (GM+/+ M+/+) mice. All toothless (M-/-) mice had signifiσantly reduσed survival σompared with wild-type and GM-CSF deficient littermates, regardless of whether they were only M-CSF deficient, or both GM- and M-CSF defiσient (Figure 2) . Median survivals were: GM+/+M+/+ and GM-/- M+/+, not attained with median follow-up for 7 months; M-/- GM+/+ or +/-, 231 days (n=27); GM-/- M-/-, 71 days (n=38) . The median ages at death for these two groups of M-/- mice were 33 and 41 days respectively. The median survival of M-/- GM+/+ or +/- miσe was signifiσantly shorter than that of GM+/+ M+/+ miσe (p=0.03), and that of GM-/- M-/- miσe was signifiσantly shorter than that of other M-/- miσe (p=0.01). Animal husbandary diffiσulties contributed to the death of most M-/- mice, but at histological examination 19/19 GM-/- M-/- mice that died or were killed at ages from 24 days to 324 days beσause of apparent illness had severe lung disease and aσute lobar pneumonia at the time of death; some of the miσe killed at ages of 24 to 324 days because of apparent distress were tachypnoeiσ. Figure 18 Phenotypic Features of GM-/- M-/- Mice GM-/- M-/- mice showed the typiσal gross phenotypiσ features of op/ op miσe ie. osteopetrosis, failure of tooth eruption, and domed head shape. In addition, they all had diseased lungs with many of the features typical of the lung disease observed in GM-/- miσe. The GM-/- M-/- miσe have age-for-age a more severe and more persistent form of the pathology seen in GM-/- M+/+ miσe. Example 19 PCR diagnosis of GM-CSF and M-CSF genotype The alleliσ status of mice at the GM-CSF locus was determined by PCR as described above. GM-CSF genotypes are designated as follows: wild-type, GM+/+, heterozygous [wild-type/disrupted] GM+/-; and homozygous for the disrupted allele, GM-/-. Whilst op/ op (M-CSF genotype designated M-/-, in parallel to GM-CSF genotypes given above) are readily recognized in litters from M+/- x M+/- matings by their "toothless" phenotype, heterozygous (M+/-) and wild-type (M+/+) littermates are not distinguishable by phenotypiσ features, and in experiments with op/ op (M-/-) it has been typiσal to use a random seleσtion of M+/- and M+/+ toothed littermates as σontrols without preσise definition of their genotypiσ status (40,41) . In order to eliminate this imprecision and the heterogeneity that a possible gene-dosage effect might introduσe, partiσularly in the faσe of GM-CSF defiσienσy, a PCR-based strategy for defining allelic status at the M-CSF locus was devised. By comparison of the murine cDNA sequence (42,43) with the published incomplete genomiσ struσture of the human M-CSF gene (44), it was prediσted that the op point mutation (45) lay in an exon homologous to human exon 3. Primers σomplementary to murine σDNA sequenσes were used to amplifiy a fragment from murine genomiσ DNA σorresponding to the intron 5' of this exon, and 300 bp of the 3' end of this 1.6 kb PCR-generated fragment sequenσed. The diagnostic PCR paired a 5' sense primer from this introniσ sequenσe (5 • -TGTGTCCCTTCCTCAGATTACA-3 ' ) with a 3' antisense primer (5 ' -GGTCTCATCTATTATGTCTTGTACCAGCCAAAA-3 ' ) to generate a PCR produσt of 195 bp or 196 bp dependent on whether or not the thymidine base insertion of the op mutation was present in template DNA. Consequent to a 2 bp mis-matσh in the 3*-antisense primer (underlined), this PCR produσt σontained a seσond Bgll site dependent on whether template σontained the op thymidine insertion. The PCR produσt was digested with Bgll whiσh out at the introniσ Bgll site generating a 96 bp produσt (confirming restriction enzyme aσtivity in each PCR reaction) , and also, in the case of product generated from op template, cut the resulting 100 bp op-template-dependent fragment into diagnostic 70 and 30 bp fragments, but not the 99 bp wild-type-dependent fragment. Heterozygosity {op/÷, M+/-) σould be distinguished from homozygosity ( op/op, M-/-) on the basis of phenotype, but also on the basis of whether the fragment of 100 bp had been completely digested by Bgll, or whether uncut 99 bp fragment remained. Ethidium bromide stained agarose gel of PCR produσts generated from wild-type, op/ op and op/+ genomiσ DNA, demonstrated the diagnostiσ 70 bp and 30 bp fragments in Bgll digests of PCR produσts from op-σontaining template DNA. The latter fragment was visible only in the σase of the op/ op template. Example 20 Haematological Analysis of GM-/- IS.-/- Mice Haemoglobin and platelet levels in mice of the four genotypes mice did not differ significantly at 4-5 weeks of age, but by 18-24 weeks of age, GM-/-M-/- miσe had signifiσantly elevated hemoglobin levels. These results are summarized in Table 8. Markedly increased hemoglobin levels were found in some older GM-/- M-/- mice: e.g. one animal that was killed because of apparent distress had a hemoglobin level of 220 g/1. Rule26 Table 9 Peripheral Blood of 18-24 wk GM-CSF and M-CSF Defiσient Miσe Peripheral blood parameter Genotype Hemoglobin Platelets Leukocytes Neutrophils Lymphocytes Monocytes Eosinophils l GM M n g i xl0 9 /l xl0 9 /l xl0 9 /l xl0 6 /l xl0 9 /l xl0 6 /l i +/+ +/+ 4 17414 7411138 9.312.3 1.610.6 7.111.6 0.2110.09 0.3510.26 -/- +/+ 5 17415 9291183 8.112.3 1.310.5 6.511.7 0.2210.11 0.1210.12 +/+ -/- 3 17214 823165 6.711.4 1.210.2 5.2+1.6 0.1510.06 0.0810.10 l -/- -/- 7 185110*#® 604170#® 6.611.1* 2.1i0.9#® 4.310.9*# 0.0510.06*# 0.0710.08* n = number of mice * = p<0.05 compared to GM+/+ M+/+ # = p<0.05 compared to GM-/- M+/+ ® = p<0.05 compared to GM+/+ M-/- GM-/- M-/- miσe of 18-24 weeks of age had signifiσantly reduσed numbers of total leukoσytes due primarily to a relative lymphopenia, as has been previously reported for M-/- miσe (Table 2 and 2) . Monoσytes were present in the peripheral blood of GM-/- M-/- miσe, but in miσe of this age levels were signifiσantly lower than in wild-type and GM-/- M+/+ miσe and than those in GM+/+ M-/- miσe (Table 2). GM-/- M-/- had signifiσantly more σirσulating neutrophils than miσe defiσient in either faσtor alone, although not signifiσantly more than their age-matσhed faσtor-replete σontrols. This relative neutrophilia persisted throughout life: GM-/- M-/- miσe of 4-5 weeks of age had granuloσyte levels of 3.0.+2.4 xl0 9 /L (n=4) σompared to 1.3+.0.7 xl0 9 /L for age-matσhed GM+/+ M+/+ (n=33) and 3 older miσe of age 26, 31 and 47 wks had granuloσyte levels of 1.74, 4.37 and 7.7 xl0 9 /l respeσtively. Despite the relative monoσytopenia, the diseased lungs of GM-/- M-/- miσe σontained large numbers of foamy alveolar maσrophages, indiσating that at least qualitatively monoσytes were available for host defenσe in tissues-. Miσe at 4-5 weeks, 18-24 and 28 weeks, were also σompared at the results are summarized in Table 9. These results are σonsistent with those in Table 8. Table 10 Peripheral Blood of GM-CSF and M-CSF Deficient Mice Peripheral blood parameter Age Genotype Hemoglobin Platelets Leukocytes Neutrophils Lymphocytes Monocytes Eosinophils wks GM M n g/i xl0 9 /l xl0 9 /I xl0 9 /l xl0 9 /l xl0 9 /I xl0 9 /l 4-5 +/+ +/+ 16 134118 771186 6.912.8 1.310.7V 5.612.4 0.0310.04 ND -/- i +/+ 33 142120 7241216 6.812.6 1.7+1.5V 5.112.0 0.0710.16 ND +/+ -/- nil 0.17+0.09 -/- -/- 4 14715 7471131 5.812.7 3.012.4V 2.712.4 0.1710.09 ND 18-24 +/+ +/+ 4 17414 7411138 9.312.3 1.610.6 7.111.6 0.21+0.09 0.3510.26 -/- +/+ 5 17415 9291183 8.112.3 1.310.5 6.511.7 0.22+0.11 0.1210.12 +/+ -/- 3 17214 823165 6.711.4 1.210.2 5.211.6 0.1510.06 0.0810.10 -/- -/- 7 185110*#® 604170#® 6.611.1* 2.1+0.9#® 4.310.9*# 0.0510.06*# 0.0710.08* 28 -/- -/- 2 175 638 5.3 3.06V 2.2 0.06 n = number of mice * = p<0.05 compared to GM+/+ M+/+ # = p<0.05 compared to GM-/- M+/+ ® = p<0.05 compared to GM+/+ M-/- V = total granulocyte count (ie. neutrophils and eosinophils) ND = not determined The mice of genotype GM-/-, M-/- show features typical of both the CSF-1-/- genotype, such as osteopetrosis and failure of tooth eruption, and of the GM-CSF-/- genotype, such as propensity to infection, especially pneumonia caused by Gram-negative organisms. These pneumonias are usually fatal. For example, in one group of four GM-/-, M-/- animals, one was found dead at the age of 8 weeks, and pneumonia caused by Klebsiella oxytoca was confirmed bacteriologically. Three animals were killed after being found seriously ill; one, killed at six weeks had Klebsiella oxytoca pneumonia, one, killed at six weeks had a facial abscess caused by a -Streptococcus species, and one, killed at twenty weeks had pneumonia caused by Pasteurella pneumotropica. These doubly deficient mice have lung pathology presenting the same features as seen in GM-CSF deficient mice. Despite the deficienσy of CSF-1, however, these mice still have monocytes/macrophages at normal or near-normal levels. Thus notwithstanding the double-deficiency these mice are able to maintain steady-state granulopoiesis and monopoiesis. References cited herein are listed on the following pages, and are incorporated herein by this reference. The following words used herein are trade marks: Araldite, Epon, Genescreen Plus, Geneticin, Sysmex. It will be apparent to the person skilled in the art that while the invention has been described in some detail for the purposes of clarity and understanding, various modifications and alterations to the embodiments and methods described herein may be made without departing from the scope of the inventive concept disclosed in this specification. REFERENCES 1. Gasson J.C. Blood, 1991 721131-1145. 2. Metcalf D., Begley C.G., Williamson D.J., Nice E.C., De Larmarter J.D., Mermod J-J., Thatcher . , Schmidt A. Exp. Hematol., 1987 3,5. 1-9. 3. Lang R.A., Metcalf D., Cuthbertson R.A., Lyons I., Stanley E., Kelso A., Kannourakis G., Williamson D.J., Klintworth G.K., Gonda T.J., Dunn A.R. Cell, 1987 51 675-686. 4. Johnson G.R., Gonda T.J., Metcalf D., Hariharan I.K., Cory S.A. EMBO J., 1989 8.441-448. 5. Metcalf D. Science, 1991 254 529-533. 6. Mortensen B.T., Schifter S., Pedersen L.B., Jensen A.N., Hovgaard D., Nissen N.I. Exp. Hematol., 1993 .2JL 1366-1370. 7. Lieschke, G.J., Dunn, A.R. "Physiologic Role of Granulocyte Colony Stimulating Factor: Insights from In Vivo Studies" Molecular Biology of Haematopoiesis, 1992 2. 201-216 (Intercept Ltd, Andover, U.K.) 8. Evans, M.J. Mol. Biol. Med., 1989 6.557-565 9. Capeσchi, Trends in Genetics, 1989 5_ 70-76 10. Smithies, O. Trends in Genetics, 1993 9_ 112-116 11. Roller, B.H. and Smithies, O. Annual Rev. Immunol., 1992 Q_ 705- 12. Corcoran, L.M. Today' s Life Science, 1994 6 14-20 13. Miyatake S., Otsuka T., Yokota T., Lee F., Arai K. EMBO J., 1985 4, 2561-2568. 14. Stanley E., Metcalf D., Sobieszczuk P., Gough N.M. , Dunn A.R. EMBO J., 1985 4 . 2569-2573. 15. Tybulewicz V.L.J., Crawford C.E., Jackson P.K., Bronson R.T., Mulligan R.C. Cell, 1991.65. 1153-1163. 16. Gough N.M., Metcalf D., Gough J., Grail D., Dunn A.R. EMBO J., 1985 4. 645-653. 17. Handyside A.H., O'Neil G.T., Jones M., Hooper M.L. Roux's Arch. Dev. Biol., 1989 198 8-55. 18. Mann G.B., Fowler K.J., Gabriel A., Nice E.C., Williams R.L., Dunn A.R. Cell, 1993 21249-261. 19. Metcalf D. The Hemopoietic Growth Factors (Elsevier, Amsterdam) 1984 20. Kelso A., Gough N.M. Growth Factors, 1989 1.165-177. 21. Metcalf D. Proc. Natl. Acad. Sci. USA, 1991 J38 . 11310-11314. 22. Harlow E., Lane D. Antibodies; a laboratory manual (Cold Spring Harbor Laboratory, NY) 1988 23. Morse H.C., Davidson W.F., Yetter R.A., Coffman R.L. Cell. Immunol., 1982 2-Q.311-320. 24. Yelton D.E., Desaymard C, Scharff M. Hybridoma, 1981 1. 5-11. 25. Dialynas D.P., Quan Z.S., Wall K.A., Pierres A., Quintans J, Loken M.R., Pierres M., Fitch F.W. J. Immunol., 1983 131 2445-2451. E SHEET Rule M>) 26. Ledbetter J.A., Herzenberg L.A. Immunol. Rev., 1989 .49. 63-90. 27. Metcalf D. Blood, 1993 J32. 3515-3523. 28. Shelburne J.D., Wisseman C.L., Broda K.R., Roggli V.L., Ingram P. in Diagnostic Electron Microscopy, eds. Trump B.F. & Jones R.T. (John Wiley & Sons, New York), 1983 4.475-532. 29. Rosen S.H., Castleman B., Liebow A.A. N. Engl. J. Med., 1958 £58.1123-1142. 30. Nogee L.M., De Mello D.E., Dehner L.P., Colten H.R. N. Engl. J. Med., 1993 328 406-410. 31. Jones C.C. Am. J. Med., 1960 29.713-722. 32. Beck J.M., Warnock M.L., Curtis J.L., Sniezek M.J., Arraj-Peffer S.M., Kaltreider H.B., Shellito J.E. Am. J. Respir. Cell Mol. Biol., 1991 5. 186-197. 33. Bilyk N., Holt P.G. J. Exp. Med., 1993 177 1773-1777. 34. Smith S.M., Lee D.K.P., Lacy J., Coleman D.L. Am. J. Respir. Cell Mol. Biol., 1990 2_ 59-68. 35. Chrane, H.T., Metcalf, D., Cheers, C. Immunology, 1990 21377-382 36. Frenck, R.W., Sarman, Harper, T.E., Buescher, E.S. J. Infect. Dis., 1990 162 109-114 37. Morrissey, P.J., Charrier, K. J. Immunol., 1990 144 557-561 38. Iida, J., Saiki, L., Ishihara, C, Azuma, Vaccine, 1989 1_ 229-233 39. Freund, M., Kleine, H.-D. Infection, 1992 2 Suppl. 2 S88-S90 40. Marks, S.C. , Lane, P.W. J. Heredity, 1976 §1_ 11-18 41. Wiktor-Jedrzejczak, W., Ahmed, A., Szczylik, C, Skelly, R.R. J. Exp. Med., 1982 156 1516-1527 42. Ladner, M.B., Martin, G.A., Noble, J.A., Wittman, V.P., Warren M.K., McGrogan, M., Stanley, E.R. Proc. Natl. Acad. Sci., U.S.A., 1988.85. 6706-6710 43. DeLamarter, J.F., Hession, C, Semon, D., Gough, N.M., Rothenbuhler, R., Mermod, J-J. Nuc. Acids Res., 1987 .15 2389-90 44. Kawasaki, E.S., Ladner, M.B. In Dexter TM, Garland JM Testa NG eds Colony Stimulating Factors New York: Marcel Dekker 1990 155-176 45. Yoshida, H., Hayashi, S-I. ,Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L.D., Nishikawa, S-I. Nature, 1990 45.442-444 46. Stanley, E., Leischke, G.J., Grail, D. et al Proc. Natl. Acad. Sci., U.S.A., (in press) 47. Pollard, J.W., Hunt J.S., Wiktor-Jedrzejczak, W., Stanley, E.R. Developmental Biol., 1991 148 273-283

Claims: THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS: 1. A non-human animal carrying a disruption of a gene encoding a colony stimulating factor. 2. A non-human animal according to Claim 1 carrying a disruption of the gene encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) , such that expression of GM-CSF is disrupted. 3. A non-human animal according to Claim 2, in which said disruption results in inability of spleen cells from the non-human animal to produce detectable levels of bioactive GM-CSF. 4. A non-human animal according to Claim 2 or Claim 3, which is a mouse. 5. A non-human animal according to any one of Claims 2 to 4, in which the gene encoding GM-CSF is completely inactivated. 6. A non-human animal according to any one of Claims 2 to 5, which carries a mutation comprising deletion of exons 1 and 2 and intron 1 between Seal and Smal restriction sites of the gene encoding GM-CSF. 7. A non-human animal according to any one of Claims 2 to 6, which carries one or more additional mutations which result in disruption of a specific gene. 8. A non-human animal according to Claim 7, wherein said additional mutation causes disruption of a gene encoding a growth factor selected from the group consisting of granulocyte colony-stimulating-factor (G-CSF), colony- stimulating-factor-1 (CSF-1); leukaemia inhibitory factor (LIF), and transforming growth factor-βl (TGF-βl), or of a cytokine. 9. A non-human animal according to Claim 8, wherein the cytokine is an interleukin. 10. A non-human animal according to Claim 9, wherein the interleukin is selected from the group consisting of interleukin-2, interleukin-3 and interleukin-6. 11. A non-human animal according to Claim 10, which is a mouse, in which the genes for GM-CSF and CSF-1 are disrupted, and in which said mouse is produced by crossing a mouse according to any one of Claims 2 to 6 with an op/op mouse. 12. A non-human animal according to Claim 1 carrying a disruption of the gene encoding granulocyte colony- stimulating factor (G-CSF), such that expression of G-CSF is disrupted. 13. A non-human animal according to Claim 12, in which said disruption results in inability of lung cells from the animal to produce detectable levels of bioactive G-CSF. 14. A non-human animal according to Claim 12 or Claim 13, which is a mouse. 15. A non-human animal according to any one of Claims 12 to Claim 14, in which the gene encoding G-CSF is completely inactivated. 16. A non-human animal according to any one of Claims 12 to 15, which carries a mutation comprising a deletion from the Ncol restriction site in exon 1 which encompasses the translation initiation codon ATG to the -BamHI restriction site in exon 3 of the gene encoding G-CSF. 17. A non-human animal according to any one of Claims 12 to 16, which carries one or more additional mutations which result in disruption of a specific gene. 18. A non-human animal according to Claim 17, wherein said additional mutation causes disruption of a gene encoding a growth factor selected from the group consisting of granulocyte-macrophage colony stimulating-factor (GM- CSF), colony-stimulating-factor-1 (CSF-1); leukaemia inhibitory factor (LIF) , and transforming growth factor-βl (TGF-βl), or of a cytokine. 19. A non-human animal according to Claim 18, wherein the cytokine is an interleukin. 20. A method of testing the efficacy of a putative method of treatment of alveolar proteinosis, comprising the step of subjecting a non-human animal according to any one of Claims 2 to 11 to said putative treatment. 21. A method according to Claim 20, wherein said putative treatment is a chemotherapeutic agent. 22. A method according to Claim 20 or Claim 21, in which the putative treatment is selected from the group consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) granulocyte-colony stimulating factor (G- CSF), colony-stimulating-factor-1 (CSF-1); leukaemia inhibitory factor (LIF), and transforming growth factor-βl (TGF-βl), or a cytokine. 23. A method according to Claim 21, wherein the chemotherapeutic agent is GM-CSF. 24. A method of testing the efficacy of a putative treatment for infectious disease, comprising the step of subjecting a non-human animal according to any one of Claims 1 to 19 to said putative treatment. 25. A method according to Claim 24, wherein said infectious disease is a bacterial, fungal or viral infection of the lung. 26. A method according to Claim 24 or Claim 25, in which said bacterial infection is an opportunistic infection of the type to which immunocompromised or immunodeficient individuals are prone, or an infection which is intractable to currently-available therapies. 27. A method according to Claim 26 wherein the opportunistic infection is one to which patients suffering from acquired immunodeficiency syndrome (AIDS) are susceptible. 28. A method of treatment of alveolar proteinosis and/or of pulmonary infection, comprising the step of administering to a subject in need of such treatment an effective amount of GM-CSF. 29. A method according to Claim 28, wherein GM-CSF is administered locally to the lung. 30. A method according to Claim 28 or Claim 29, in which said GM-CSF is administered as an aerosol, via a nebuliser or via an endotracheal tube. 31. A method according to any one of Claims 28 to 30, wherein the GM-CSF is administered as adjunctive therapy to other treatments. 32. A method according to any one of Claims 29 to 31, wherein the dose of GM-CSF is from 0.1 μg/kg body weight to 20 μg/kg body weight. 33. A method of treatment of pulmonary infection, comprising the step of administering to a subject in need of such treatment an effective amount of G-CSF. 34. A method according to Claim 33, wherein G-CSF is administered locally to the lungs. 35. A method according to Claim 33 or Claim 34, in which said G-CSF is administered as an aerosol, via a nebuliser or via an endotracheal tube. 36. A method according to any one of Claims 33 to 35, wherein the G-CSF is administered as adjunctive therapy to other treatments. 37. A method according to any one of Claims 33 to 35, wherein the dose of G-CSF is from 0.1 μg/kg body weight to 20 μg/kg body weight. 38. A factor which is involved in regulation of steady-state haematopoiesis, and which is present in animals in which expression of GM-CSF is disrupted. 39. A factor according to Claim 38, which is present in animals whose spleen cells are incapable of producing detectable levels of bioactive GM-CSF. 40. A factor according to Claim 38 or Claim 39, which is also present in animals in which expression of both GM- CSF and G-CSF is disrupted. 41. A factor according to Claim 38 or Claim 39, which is also present in animals in which expression of both GM- CSF and CSF-1 is disrupted. 42. A method of treatment of a patient suffering from alveolar proteinosis, comprising the step of administering the gene encoding GM-CSF to said patient via somatic gene therapy . 43. A method according to Claim 42, in which the somatic gene therapy comprises the step of intravenous TE SHEET Rule 26) administration of a liposomal formulation of cDNA encoding GM-CSF. 44. A method of diagnosis of a colony-stimulating factor deficiency, comprising the step of testing a tissue or cell sample from a sub et suspected of suffering from such a deficiency for the absence of the gene encoding said factor. 45. A method of diagnosis of GM-CSF deficiency or of G-CSF deficiency, comprising the step of testing cells or tissue from a subject suspected of suffering such deficiency for the presence of a gene encoding GM-CSF or G-CSF respectively. 46. A method according to Claim 44 or Claim 45, wherein the test is carried out using peripheral blood cells. 47. A method according to Claim 44 or Claim 45, wherein the test is carrying out using tissue obtained by lung biopsy. 48. A targeting veσtor for disruption of a gene encoding GM-CSF, as described herein with reference to Figure ϊ. 49. A targeting vector for disruption of a gene encoding G-CSF, as described herein with reference to Figure 5. 50. A cell line derived from a non-human animal according to any one of Claims 1 to 19. 51. A cell line according to Claim 50, which is a bone-marrow stromal cell line. 52. A composition suitable for local administration to the lung, comprising GM-CSF and/or G-CSF and a pharmaceutically-acceptable carrier. LUDWIG INSTITUTE FOR CANCER RESEARCH e 26

Inventors: DUNN ASHLEY ROGER, FOWLER KERRY J, GRAIL DIANNE, LIESCHKE GRAHAM JOHN, STANLEY EDOUARD GUY, DUNN, ASHLEY, ROGER, FOWLER, KERRY, J., GRAIL, DIANNE, LIESCHKE, GRAHAM, JOHN, STANLEY, EDOUARD, GUY
Applicants: DUNN ASHLEY ROGER, FOWLER KERRY J, GRAIL DIANNE, LIESCHKE GRAHAM JOHN, LUDWIG INST CANCER RES, STANLEY EDOUARD GUY, DUNN, ASHLEY, ROGER, FOWLER, KERRY, J., GRAIL, DIANNE, LIESCHKE, GRAHAM, JOHN, LUDWIG INSTITUTE FOR CANCER RESEARCH, STANLEY, EDOUARD, GUY
Application year: 1994
Main classification: C12N15
IPC codes: A01K67, A61K9, A61K35, A61K38, A61K48, A61K49, A61P11, A61P31, A61P37, C07K14, C12N15, C12Q1